Enovis (NYSE:ENOV) Trading Down 7.9% Following Analyst Downgrade

Enovis Corporation (NYSE:ENOV) was down 7.9% during trading on Tuesday after Zacks Research downgraded the stock from a hold rating to a strong sell rating. The stock traded as low as $20.11 and last traded at $20.2730. 87,471 shares were traded during mid-day trading, a decline of 92% from the average session volume of 1,058,294 shares. The stock had previously closed at $22.02.

A number of other research firms have also issued reports on ENOV. Wall Street Zen lowered shares of Enovis from a “buy” rating to a “hold” rating in a report on Sunday. William Blair initiated coverage on shares of Enovis in a research note on Friday, April 17th. They issued an “outperform” rating on the stock. BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Enovis in a research report on Friday, May 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. Finally, Evercore reiterated an “outperform” rating and issued a $36.00 price objective on shares of Enovis in a report on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.50.

Insider Activity

In other news, insider Oliver Engert acquired 1,200 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was purchased at an average price of $21.62 per share, with a total value of $25,944.00. Following the completion of the acquisition, the insider owned 51,840 shares of the company’s stock, valued at $1,120,780.80. This trade represents a 2.37% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have bought a total of 4,200 shares of company stock valued at $92,084 over the last ninety days. Corporate insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

A number of hedge funds and other institutional investors have recently made changes to their positions in ENOV. Rubric Capital Management LP acquired a new position in Enovis in the third quarter valued at approximately $83,435,000. Paradigm Capital Management Inc. NY raised its position in Enovis by 70.2% in the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock valued at $40,420,000 after purchasing an additional 732,917 shares during the period. AQR Capital Management LLC lifted its stake in shares of Enovis by 682.6% in the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock valued at $15,627,000 after purchasing an additional 434,646 shares during the last quarter. Front Street Capital Management Inc. grew its holdings in shares of Enovis by 106.1% during the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock worth $16,973,000 after purchasing an additional 384,124 shares during the period. Finally, Quantinno Capital Management LP grew its holdings in shares of Enovis by 130.8% during the 1st quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock worth $13,752,000 after purchasing an additional 342,556 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Stock Down 3.4%

The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -1.01 and a beta of 1.39. The business has a 50-day moving average of $23.28 and a 200-day moving average of $23.90. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.07. The company had revenue of $589.15 million during the quarter, compared to analyst estimates of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. Enovis’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, sell-side analysts expect that Enovis Corporation will post 3.12 EPS for the current year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.